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Abstract 
Loss of function mutations in human Oligophrenin1 (OPHN1) gene are responsible for  
syndromic intellectual disability (ID) associated with cerebellar hypoplasia and cerebral 
ventricles enlargement. Functional studies in rodent models suggest that OPHN1 linked ID is 
a consequence of abnormal synaptic transmission and shares common pathophysiological 
mechanisms with other cognitive disorders. Variants of this gene have been also identified in 
autism spectrum disorder and schizophrenia. The advanced understanding of the 
mechanisms underlying Oligophrenin1-related ID, allowed us to develop a therapeutic 
approach targeting the RHOA/ROCK signalling pathway and repurpose Fasudil- a well-
tolerated ROCK and PKA inhibitor- as a treatment of ID. We have previously shown ex-vivo 
its beneficial effect on synaptic transmission and plasticity in a mouse model of the OPHN1 
loss of function.  
Here, we report that chronic treatment in adult mouse with Fasudil, is able to 
counteract vertical and horizontal hyperactivities, restores recognition memory and limits the 
brain ventricular dilatation observed in Ophn1−/y. However, deficits in working and spatial 
memories are partially or not rescued by the treatment.  These results highlight the potential 
of Fasudil treatment in synaptopathies and also the need for multiple therapeutic approaches 
especially in adult where brain plasticity is reduced. 
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Introduction 
Intellectual Disability (ID) is defined by an overall Intelligence Quotient (IQ) lower than 70 
associated with deficit in conceptual, social, and practical adaptive skills with an onset before 
the age of 18 years (1). The clinical spectrum of cognitive deficit varies widely from non-
syndromic ID to Autism Spectrum Disorder (ASD) and is estimated to affect 3-5% of the 
population (2). The causes of ID are heterogeneous and include genetic and/or 
environmental factors that influence the development and function of the Central Nervous 
System (CNS) during the pre-, peri-, or post-natal period. Genetic causes are responsible for 
40 to 50% of moderate to severe ID (IQ < 50), whereas environmental factors primarily 
contribute to mild ID (50 < IQ < 70) (1). Genes that are involved in ID with a preserved CNS 
organization (i.e., normal MRI scan) are likely to encode proteins that are necessary for the 
development of cognitive functions. Compelling evidence indicates that one major functional 
group of ID-related proteins corresponds to proteins that are enriched at synaptic 
compartments, and regulates synaptic activity (3, 4). Amongst them, several signalling 
molecules of the RhoGTPases pathway have been found mutated in ID patients (5).  
Mutations in Oligophrenin1 gene (OPHN1), which encodes a RhoGAP are 
responsible for syndromic ID with moderate to severe cognitive impairment associated with 
cerebellar hypoplasia predominant in the vermis and brain ventricular enlargement (6-8). 
Ophn1 gene loss of function in mouse mimics the human pathology apart the cerebellar 
hypoplasia (9). Compelling results from our group and others suggest that part of the ID in 
OPHN1 patients is a consequence of abnormal synaptic transmission linked to enhanced 
RhoA signalling and deregulation of actin cytoskeleton at the inhibitory and excitatory 
synapse (10, 11). OPHN1 regulates clathrin-mediated endocytosis and the loss of its function 
reduces the internalization and recycling of synaptic vesicles and α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptors (AMPAR) resulting in deficit in synaptic plasticity 
(12, 13). Disruption of OPHN1 and Homer1b/c protein interaction also results in the 
displacement of the endocytic zone from the Post-Synaptic Density (PSD) and impairs the 
addressing and recycling AMPAR (13). In addition Ophn1 mRNA translation at the synapse 
is locally increased upon type1-metabolotropic receptors (mGluR1) activation suggesting that 
OPHN1 is a “mediator” of Long Term Depression (LTD) that controls the strength of the 
synapse during intense glutamatergic stimulation (14, 15). These functional deficits are 
associated with changes in the density and morphology of dendritic spines, the support of 
most excitatory synapses (9-11, 16). OPHN1 also interacts with Rev-erb alpha, a nuclear 
receptor that represses transcriptional activity of circadian clock genes delineating a new 
communication between synapse and nucleus (17). Because of hyperactivation of RHOA 
signalling pathway in Ophn1 KO cells inhibiting one of its effector the RHO-kinases ROCK 
was able to restore synaptic transmission and plasticity in Ophn1−/y hippocampal slices (10, 
12). More recently we discovered that not only ROCK but also Protein Kinase A (PKA) 
activities were increased in some brain regions of the Ophn1−/y mice (12). In this context, oral 
administration of Fasudil, a ROCK and PKA kinases inhibitor was able to rescue the fear 
extinction deficit observed in Ophn1 KO mice (18) 
In the present study, we expand these findings by targeting in vivo these pathways in adult 
mice and perform some neurological and behavioural phenotypic analysis focusing 
particularly on previously characterized deficits (9). Fasudil or HA1077, which is already used 
in Japan to cure cerebrovascular diseases was administered orally in adult during 3 months 
 by guest on M
ay 5, 2016
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
	 4	
(19). It is a well-tolerated and safe molecule that crosses the brain blood barrier and its 
administration in rat models of Alzheimer improved their learning and memory performances 
(20). Altogether, this result encourages preclinical trials for additional indications in 
neurodevelopmental diseases such as the OPHN1 linked ID.  
 
 
Results 
Inhibition of the RHOA/RHO-kinase and PKA signalling pathways in Ophn1-/y mouse 
brain  
As a GAP protein, OPHN1 stimulates GTPase activity of RHOA and lowers the effector 
activity of the Rho kinase, ROCK (figure 1A). We previously showed that RHOA/ROCK 
pathway is over-activated in Ophn1-/y leading to the increase of ROCK’s target 
phosphorylation such as the myosin phosphatase target subunit-1 (MYPT1) (12). MYPT1 
phosphorylation by ROCK reduces the phosphatase activity toward the Myosin light chain 
(MLC) resulting in the increase of acto-myosin contraction (21). Ex vivo treatments by the 
ROCK inhibitors Y27632 or Fasudil decreased the phosphorylation of MYPT1, restored the 
endocytosis deficit in astroglial cells, the inhibitory and excitatory transmissions, the synaptic 
plasticity and network activity in hippocampal slices from the KO mice (10, 12, 22). We more 
recently identified higher PKA activities in the cortex and hippocampus of Ophn1-/y resulting 
in a deficit of Long-Term Potentiation (LTP) at cortico-Lateral Amydala synapses together 
with a deficit in fear extinction memory (18). Daily administration of Fasudil at 3 mg during 3 
weeks by oral administration was able to restore the level of PKA activity to controls and also 
the behaviour of the Ophn1-/y with little effect on Ophn1+/y (18). Whereas the molecular links 
between these two pathways in the context of loss of OPHN1 function are still unclear, the 
dosage and the route of administration of Fasudil encourage to the therapeutic schemas that 
we used in this new study: adult males of 2 or 4 months were given orally a daily dose of 3 
mg for a total of 3 months (figure 1B and 1C). Behaviour, brain anatomy (RMI) and dendritic 
spine morphology were evaluated during and after the 3 months of treatment. 
 
Fasudil restores body weight, hyperactivity, and motor ability phenotypes in Ophn1-/y 
mice 
 
We previously reported that loss of OPHN1 function in mice leads to novelty-driven 
hyperactivity, decreases lateralization and alters spatial memory with no or little effect on 
motor coordination, on anxiety related behaviours and in social interactions (9). Therefore we 
tested whether ROCK/PKA inhibitions alters some behavioural parameters in Ophn1+/y and 
could rescue some of the phenotypes observed in Ophn1-/y. Chronic Fasudil treatment did 
not affect the survival rate of animals and we did not notice any side effects of Fasudil on the 
general behaviour of the treated animals. No effects on body weight or on motor coordination 
were observed after Fasudil treatment of Ophn1+/y (data not shown). Ophn1-/y males showed 
significantly decreased body weight, as compared to Ophn1+y (29.23+/-0.93 vs 31.65+/-0.70; 
genotype F(1,38)=4.58; p<0.05, post-hoc test p<0.05), such effect was corrected by Fasudil 
treatment (data not shown) and also tend to have reduced motor coordination in the rotarod 
task (figure 2A). In the elevated plus maze, the percentage of entries and the percentage of 
time in the open arms were comparable between genotypes and between treatments, 
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suggesting that neither Ophn1 deletion nor Fasudil treatment affected anxiety in this test 
(data not shown). 
We next explored the hyperactivity phenotype in different situations. In the elevated plus 
maze (Figure 2B) and also during the first 5 minutes of habituation phase of the object 
recognition task (Figure 2C), Ophn1-/y males showed significantly increased number of rears 
as compared to Ophn1+/y, a phenotype that was rescued by Fasudil without any effect on 
Ophn1+/y (Figure2B: interaction genotype x treatment F(1,36)=7.32; p<0.05, post-hoc test 
Ophn1+/y (control)  vs Ophn1-/y (control) p<0.05, post-hoc test Ophn1-/y (control)  vs Ophn1-/y 
(Fasudil) p<0.05  and  Figure 2C : interaction genotype x treatment F(1,37)=7.19, p<0.05; 
treatment F(1,37)=4.75, p<0.05; post-hoc test Ophn1+/y (control)  vs Ophn1-/y (control) p<0.05, 
post-hoc test Ophn1-/y (control)  vs Ophn1-/y (Fasudil) p<0.01). The observed hyperactivity in 
Ophn1-/y not only affects the rearing but also the locomotor activity. During the first 5 minutes 
of the habituation phase in the object recognition task Ophn1-/y mice travelled a longer 
distance in the open field compared to Ophn1+/y (Figure2D) (genotype F(1,38)=4.10, p<0.05; 
post-hoc test Ophn1+/y (control) vs Ophn1-/y (control) p<0.05). Fasudil treatment restores the 
locomotor activity back to untreated control genotype (Figure 2D) (treatment F(1,38)=4.83, 
p<0.05; post-hoc test Ophn1-/y (control)  vs Ophn1-/y (Fasudil) p<0.05). In addition, both 
locomotors and rearing activities were also increased in Ophn1-/y mice during the acquisition 
trial of object recognition (supplemental figure 1). In this context Fasudil also restored similar 
levels to Ophn1+/y mice. Altogether Fasudil chronic treatment largely improves the Ophn1-/y 
condition regarding the hyperactivity. 
Improvement of recognition but not working and spatial reference memory deficits 
In the recognition task animals were allowed to discriminate between a novel object and a 
familiar one. Neither genotype nor treatment alters significantly the object recognition 
performance (Figure 3A) (overall statistical analysis with 2 way ANOVA). Nevertheless, 
vehicle-treated Ophn1+/y, Fasudil-treated Ophn1+/y and Fasudil-treated Ophn1-/y, but not 
vehicle-treated Ophn1-/y, showed recognition performance significantly above the 50% 
chance level (p<0.05), which might suggest altered recognition memory in mutants, and 
protective effect of Fasudil (Figure 3A). 
In the previous characterization of the Ophn1-/y (9), we reported the hyperactivity of the mice 
in the Y-maze task but did not explore the spontaneous alternation as a measure of the 
working memory. We now extended these first studies and found that loss of OPHN1 
function reduces the frequency of spontaneous alternation (genotype F(1,38)=2.84, p<0.10; 
post hoc test Ophn1+/y (control) vs Ophn1-/y (control) p<0.05). Even if not striking, such 
deficits were reduced in ophn1-/y treated with Fasudil; their performance was statistically 
comparable to that of Ophn1+/y groups. This observation suggests, even with reduced 
strength, that Fasudil has potency to rescue working memory deficits, supporting data 
observed in the object recognition task (Figure 3B). 
Next we investigated the effect of Fasudil on the spatial reference memory phenotype linked 
to Ophn1 deficiency. The latency (data not shown) and distance (Figure 3C) to locate a 
submerged platform decreased significantly in all groups of mice as testing progressed 
(Ophn1+/y: learning F(4,100)=28.55, p<10-4 and Ophn1-/y: learning F(4,90)=14.23, p<10-4). On the 
other hand, a significant effect of genotype was observed concerning these parameters 
(vehicle: genotype F(1,95)=12.67, p<0.001, and Fasudil: genotype F(1,95)=13.01, p<0.001). 
Ophn1-/y mice, whatever the treatment, showed significantly longer latencies (data not 
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shown) and distances to the hidden platform, as compared to Ophn1+/y counterparts (Vehicle: 
post hoc tests p<0.05 for days 2 and 3 and Fasudil: post hoc tests p<0.01 for day 3), 
confirming the delayed spatial learning in Ophn1-/y (9) and showing little or no improvement 
after treatment. In agreement with this observation, the preference for the target quadrant 
(data not shown) and the number of platform crosses (Figure 3D) were reduced in Ophn1-/y 
mice (genotype F(1,38)=13.02, p<0.001, vehicle post-hoc test p<0.05) with no effect of Fasudil. 
Reduction of the brain ventricle dilatation 
To investigate Fasudil effect on brain anatomy, 6 fixed brains from each group of animals 
were processed for magnetic resonance imaging (MRI). Two Ophn1-/y males from the 
untreated group displayed hydrocephalus and were excluded from the analysis. First, we 
measured the whole brain volume and did not notice any effect of the genotype or the 
treatment on this parameter (Figure 4C-D). In accordance with our previous study (9), 
untreated Ophn1-/y mice show an increase of the relative ventricular size compared to their 
Ophn1+/y counterparts (genotype F(1,18)=7.00, p<0.05; untreated Ophn1-/y vs Ophn1+/y post 
hoc test p<0.05) (Figure 4A-B). Fasudil treatment tends to decrease the size of the ventricle 
of Ophn1-/y with no effect on Ophn1+/y (F(1,18)=4.99, p<0.05; untreated vs treated Ophn1-/y post 
hoc test p< 0,10) (Figure 4A-B). In conclusion, inhibition of RHO kinase ameliorates the brain 
lateral ventricular dilatation observed in Ophn1 deficient mice and limits the development to 
hydrocephaly. Indeed none of the six treated Ophn1-/y mice were affected by this condition. 
Genotype-specific response of dendritic spine morphology  
Ophn1 deletion reduced the density of mushroom-shaped dendritic spines decorating apical 
dendrites in CA1 region of hippocampus in 8-week-old mice (8). In this study we used a 
Diolistic approach to fluorescently label dendrites and spines of pyramidal neurons in the 
same hippocampal area (23). In order to explore the effect of ROCK inhibition, we treated 8-
week-old Ophn1+/y and Ophn1-/y male mice with Fasudil or vehicle solution for 12 weeks 
(figure 1C). Five-month-old mice of the four experimental groups (n = 2/4 animals/group) 
were processed for morphological analyses of dendritic spines on and apical dendrites 
imaged 100-200 µm away from the soma (figure 5A).  
We found that while dendrites from Ophn1+/y and Ophn1-/y mice were decorated with similar 
density of mushroom-, thin-shaped (figure 5C and D) and stubby spines (data not shown), 
the density of filopodia protrusions was significantly increased in Ophn1-/y mice (figure 5B). 
Also, no significant differences of spine morphology (i.e. head diameter and neck length) 
were observed between genotypes (figure 5 E,F and data not shown). However, we 
observed that Fasudil treatment produced genotype-specific effects on both the density and 
the morphology of dendritic spines. Interestingly, Fasudil specifically increased the density of 
thin-shaped spines in Ophn1+/y mice when compared to untreated animals (figure 5C; p < 
0.05). Moreover our analyses revealed that after Fasudil treatment, Ophn1-/y mice presented 
with an higher number of mushroom-shaped spines and a lower number of thin-shaped 
spines than treated Ophn1+/y animals (figure 5D and 5C; Two-way ANOVA. mushroom: 
(interaction), F(1,10) = 5.34, p = 0.043; (genotype), F(1,10) = 7.96, p = 0.018; (Fasudil) F(1,10) = 
1.57, p = 0.238. thin: (interaction), F(1,10) = 9.96, p = 0.010; (genotype), F(1,10) = 9.13, p = 
0.013; (Fasudil) F(1,10) = 7.05, p= 0.024). In addition, Fasudil treatment produced no effects 
on the density stubby spines (data not shown). Intriguingly, Fasudil treatment was able to 
rescue the abnormal number of filopodia shown by Ophn1-/y mice (figure 5B; Two-way 
ANOVA. filopodia: (interaction), F(1,10) = 1.28, p = 0.285; (genotype), F(1,10) = 4.95, p = 0.049; 
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(Fasudil) F(1,10) = 2.21, p = 0.168). Moreover, we found that after Fasudil treatment Ophn1-/y 
mice showed shorter neck-length of mushroom-shaped spines and smaller head-diameter of 
thin-shaped spines than treated Ophn1+/y animals (figure 5E and 5F; Two-way ANOVA. 
mushroom neck lenght: (interaction), F(1,10) = 6.04, p = 0.034; (genotype), F(1,10) = 8.17, p = 
0.017; (Fasudil) F(1,10) = 0.73, p = 0.412. thin head diameter: (interaction), F(1,10) = 1.33, p = 
0.276; (genotype), F(1,10) = 10.21, p = 0.010; (Fasudil) F(1,10) = 1.62, p= 0.232). Altogether, we 
found that compared to untreated Ophn1+/y animals dendritic spines are normalized in 
Ophn1-/y mice after 5 months of age while the density of filopodia protrusion is increased, and 
that Fasudil treatment differentially affects the dendritic spines in Ophn1+/y and Ophn1-/y mice. 
 
Discussion 
The advanced understanding of pathophysiological mechanisms underlying OPHN1-
related ID, allowed us to develop a therapeutic approach targeting the RHOA/ROCK and 
PKA pathways and reposition a pharmacological drug Fasudil for ID treatment. Previous in 
vitro and ex-vivo experiments have demonstrated the beneficial effect of ROCK and PKA 
inhibitions on synaptic transmission and on fear conditioning (10, 12, 18, 22).  
 Here we test in the Ophn1-/y mouse whether Fasudil administration rescues other 
behavioural deficits and brain anatomy alterations. This study allowed us to replicate the 
differences between genotype on an independent cohort raised in a different location. Finally 
we shows that chronic treatment of adult male for 3 months counteracts the brain ventricular 
dilatation (BVD) and also novelty driven hyperactivity but has little beneficial effects on 
spatial working and reference memories.  
Part of the ID in OPHN1 patients is a consequence of a synaptopathy with abnormal 
synaptic transmission linked to enhanced RHOA and PKA signalling and deregulation of 
actin cytoskeleton at the inhibitory and excitatory synapses. These functional deficits are 
associated with changes in neuronal morphology mainly affecting the dendritic spines, which 
support most of the excitatory synapses (9-11, 16). Acute treatment by the specific ROCK 
inhibitor Y27632 in hippocampus restores excitatory and inhibitory transmissions without 
rescuing the dendritic spines phenotypes suggesting that either alterations of spine is a 
consequence of transmission deficit or that the morphological response is delayed compared 
to the synaptic transmission (10). Here, we found that the dendritic spine density and 
morphology of CA1 pyramidal neurons from Ophn1-/y are similar to controls at 5 months old 
(this study) while Ophn1-/y retained an higher density of dendritic filopodia, an immature type 
of dendritic protrusion which density was found abnormally elevated in both autism (24) and 
Fragile-X	(25) conditions. When compared to other studies in hippocampus at different ages 
(9, 10) (supplemental figure 2A) the differences between genotype seems to attenuate 
suggesting some compensation of dendritic spine density with age similarly to what was 
observed in the Rett mouse model (23). Interestingly we recently showed that PKA activity is 
increased in some brain regions including the hippocampus but the link between Ophn1 
deficit and this increase is still unknown (18). RHOA phosphorylation by PKA is known to 
reduce RHOA activation by decreasing ROCK binding to phosphorylated RHOA (26). 
Therefore the increase of PKA would compensate for the deficit in Ophn1 and would restore 
the balance between RHO and RAC GTPases, which are known to have opposite effect on 
dendritic spine growth (supplemental figure 2B and 2C). More surprisingly, we found that the 
two genotypes show a differential response to RHO kinase inhibition by Fasudil regarding the 
density and morphology of either mature (i.e. mushroom) or immature (i.e. thin) type of 
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spines. Whereas Fasudil increases the density of thin spines in Ophn1+/y, it has no effect in 
Ophn1-/y. In contrast, after Fasudil treatment Ophn1-/y show higher mushroom spines density 
than Ophn1+/y. Morever, while Fasudil produces a decrease in the head size of thin spines 
only in Ophn1-/y, it resulted in longer neck length of mushroom spines only in Ophn1+/y. These 
differential effects of the treatments between genotype may reflect the different functions of 
ROCK1 and ROCK2 in the dendritic spines and the different role of OPHN1 in the control of 
their kinase activity (27). Alternatively, compared to the specific ROCK inhibitor Y27632, 
Fasudil also inhibits PKA activity with a similar efficacy (18, 28). The differential effects of 
Fasudil on neck length would be the consequence of the triple inhibition of the pathway in 
Ophn1+/y whereas, in Ophn1-/y, persistent activated RHOA will stimulate alternative effectors 
pathway such as CITRON/CORTACTIN/COFILIN/F-ACTIN to induce the dendritic spine 
retraction (29) (supplemental figure 2B and 2C). Interestingly, RHOA phosphorylation by 
PKA alters specifically ROCK binding but not other effectors to the GTPase (26). 
Human mutations in OPHN1 gene lead to ID together with cerebellar hypoplasia and BVD (7, 
8). Whereas the cerebellar phenotype is not reproduced in the mouse model, we previously 
showed that BVD is already present in Ophn1-/y mice at weaning (22%) and worsen with 
age (70% at 8-9 months)(9). The pathophysiological mechanism of the BVD is still not known 
but several hypotheses could be made. OPHN1 is highly expressed in the vascular 
endothelium (16, 30) and the loss of its function would alter vascular permeability due to 
activation of RHOA/ROCK pathway in these cells (31). Brain exposure to blood is detrimental 
and can lead to hydrocephaly when it occurs during foetal period and also to 
ventriculomegaly in postnatal brain (32). Pharmacological inhibition of ROCK has been to 
shown to decrease vascular permeability (33) and, in the context of Ophn1-/y, Fasudil would 
limit the exposure of the brain to blood. Alternatively OPHN1 is expressed in the choroid 
plexuses and in the ependyma lining the brain ventricles (data not shown), which are two 
structures involved in the production and circulation of the cerebro spinal fluid (CSF). OPHN1 
through the regulation of actin cytoskeleton may affect cilia morphology and/or function. 
However we observed no defect of cilia morphology in Ophn1-/y by transmission electronic 
microscopy (data not shown). Further investigations are required to explore the 
pathophysiological mechanisms of BVD and its rescue by Fasudil. 
Several animal models with hippocampal lesions (34) or with mutations affecting 
glutamate transmission (35, 36) show increased locomotor activity in various test, which has 
been commonly associated to an excess of exploratory activity when exposed to a novel 
environment. Ophn1-/y mice, which have some alterations in excitatory and inhibitory 
transmissions in hippocampus (10, 12, 22) and in other brain locations (18) display a 
hyperactivity phenotype mainly during the first 10 minutes after its introduction into another 
context. The increase of both vertical (rearing) and horizontal (locomotor) movements could 
reflect an excess of curiosity or an uncontrolled response to the stress. Interestingly, Ophn1-/y 
mice hyperactivity is completely abolished by Fasudil administration without detrimental 
effect in Ophn1+/y.  
Although chronic administration of Fasudil in adult improved recognition memory and 
rescued extinction memory deficits in Ophn1-/y, it had no effect on spatial reference memory 
deficit (Morris Water Maze) (this study and (18)). In some tests (Figure 3B and 3D) Fasudil 
treatment even tends to have detrimental effects on Ophn1+/y resulting on an apparent 
rescue due to loss of significant differences between treated mice of both genotypes (Y 
maze). Previous studies in hippocampal slice have shown that synaptic transmission and 
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plasticity but also network activities are rescued by acute ROCK inhibition using Y27632 (10, 
12, 22). In some of these studies the rescue efficacy depends on the tested conditions. 
Whereas spontaneous gamma oscillations in CA3 region of Ophn1-/y hippocampus are 
restored back to control level, kainate-induced oscillations are not (22). Similarly, Fasudil 
administration rescued cued fear conditioning extinction but not contextual conditioning 
memories (18). In the present study, the reduced beneficial effect in vivo on memory tests 
suggest that some neurodevelopmental alterations during the embryo and perinatal periods 
may not be compensated later by treatment at the adult stage. This hypothesis will deserve a 
new study starting the Fasudil treatment earlier during middle gestation (E15 days post-
coïtum) in order to restore the balance in RHO GTPase and PKA activation during the pic of 
neurogenesis (37). An alternative strategy to treat adult would be to reactivate the juvenile 
plasticity and reopen the developmental window in the adult brain using antidepressant drugs 
such as fluoxetine (38, 39) and then perform intensive training together with the 
administration of Fasudil. This strategy would restore the synaptic transmission and plasticity 
in a permissive context to rebuild new “improved” activity networks during the acquisition and 
consolidation of deficient cognitive functions. 
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Materials and Methods 
Animals and Fasudil treatment 
Two cohorts of male mice in C57BL/6N genetic background were randomly divided into four 
groups and experiments were conducted blindly to the animal caretakers and investigators. 
Fasudil hydrochloride or HA1077 (F4660, LC laboratories, Boston, MA, USA) was given 
orally ad libitum in drinking water (100 mg/kg/day). Drinking volumes (4.6ml/day) were similar 
between treated and untreated mice.  
Four weeks after the start of Fasudil delivery, 17-18 weeks-old mice from the first cohort (10-
12 per genotype and per treatment) underwent behavioural tests that lasted 8 weeks during 
which they were kept under treatment. At the end of this study, half of the animals from each 
group (genotype and treatment) were perfused with 4% paraformaldehyde for MRI analysis. 
For the other half of mice, brain regions were sampled, snap frozen, then maintained at -
80°C for subsequent molecular analysis. Animals displaying hydrocephaly were excluded 
from subsequent analyzes. 
Another cohort of mice (8 week-old) was treated for 12 weeks before dendritic spine were 
analysed. 
Testing was carried out in accordance with the EC directive 2010/63/UE and application 
decree 2013-118 dated 1st February 2013 and with the agreement of the local ethical 
committee Com’Eth (n°17) under the accreditation numbers 2012-019 and 2012-139 with YH 
as the principal investigator (accreditation 67-369). 
Behaviour 
The general health and basic sensory motor functions were evaluated using a modified 
SHIRPA protocol (40). It provides an overview of physical appearance, body weight, body 
temperature, neurological reflexes and sensory abilities. Detailed procedures for evaluation 
of motor function (rotarod test), anxiety-related behaviour (elevated plus maze, openfield) 
and learning and memory (object recognition task, Y maze and Morris water maze) were 
previously described (41) and  briefly summarize below.  
Elevated plus maze: The apparatus used was completely automated and made of PVC 
(Imetronic, Pessac, France). It consisted of two open arms (30 X 5 cm) opposite one to the 
other and crossed by two enclosed arms (30 X 5 X 15 cm). The apparatus was equipped 
with infrared captors allowing the detection of the mouse in the enclosed arms and different 
areas of the open arms. The number of entries into and time spent in the open arms were 
used as an index of anxiety. Closed arm entries were used as measures of general motor 
activity. The number of rears in the closed arms, as well as ethological parameters such as 
stretching, attempts and head dips, was also automatically scored. 
Object recognition task: The object recognition task was performed in automated open fields. 
The open-fields were placed in a room homogeneously illuminated at 70 Lux at the level of 
each open field. The objects to be discriminated were a glass marble (2,5 cm diameter) and 
a plastic dice (2 cm). Animals were first habituated to the open-field for 30 min. The next day, 
they were submitted to a 10-minutes acquisition trial during which they were placed in the 
open-field in presence of an object A (marble or dice). The time the animal took to explore 
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the object A (when the animal’s snout was directed towards the object at a distance ≤ 1 cm) 
is manually recorded. A 10-minutes retention trial is performed 3 h later. During this trial, the 
object A and another object B are placed in the open-field, and the times tA and tB the 
animal takes to explore the two objects are recorded. A recognition index (RI) is defined as 
(tB / (tA + tB)) x100. 
Y-maze spontaneous alternation: The apparatus was a Y-maze made of Plexiglas and 
having 3 identical arms (40x9x16 cm) placed at 120° from each others. Each arm had walls 
with specific motifs allowing distinguish it from the others. Each mouse was placed at the end 
of one of the three arms, and allowed to explore freely the apparatus for 5min, with the 
experimenter out of the animal’s sight. Alternations are operationally defined as successive 
entries into each of the three arms as on overlapping triplet sets (i.e., ABC, BCA ...). The 
percentage of spontaneous alternation was calculated as index of working memory 
performance. Total arm entries and the latency to exit the starting arm were also scored as 
indexes of ambulatory activity and emotionality in the Y- maze, respectively. 
Morris water maze: The water maze consisted of a white circular tank (1.50 m diameter) 
filled with opaque water. Pool temperature was adjusted to 21+1°C. For the hidden platform 
task, the escape platform (10 cm diameter) was positioned 1cm below water level in the 
centre of one of the pool quadrants. For the cued task, platform position was signaled by the 
addition of a small flag. The walls surrounding the water maze were hung with posters and 
flags, which served as visual cues and were visible during all stages of training and testing. 
Movement of the mice within the pool was tracked and analyzed with a computerized 
tracking system (ViewPoint, France). 
Animals were first trained in the hidden platform protocol (spatial learning). Mice were 
required to locate a submerged hidden platform by using only extra-maze cues. Each mouse 
received 5 blocks of training trials over five consecutive days in which they were placed in 
the pool at one of four randomized start positions, and allowed to locate the hidden platform. 
Trials lasted for a maximum of 120s and were separated by 15-20 min intervals. If a mouse 
failed to find the platform within this period, it is guided to its position by the experimenter. 
Spatial learning performance was assessed during a probe trial 1h after training, and for 
which the target platform was removed from the pool. 
Mice were then tested for cued training (visible platform), in which they were placed in the 
pool facing the edge at one of four start positions (NE, SE, SW, NW), and required to locate 
a flagged platform whose position varied across trials. Each mouse received 4 trials per day 
for 2 consecutive days. Trials lasted for a maximum of 120s and were separated by 15-20 
min intervals. If a mouse failed to find the platform within this period, it is guided to its 
position by the experimenter. 
The latency, distance and the average speed were used to evaluate performance during 
training trial. For the probe trial, the percentage of time in each quadrant and the number of 
platform crosses were used as index of spatial learning performance. 
Magnetic resonance imaging (MRI): acquisition and analysis  
Fixed brains were included in agarose and imaged with a 9.4T nuclear magnetic resonance 
scanner (Bruker BioSpin, Ettlingen, Germany). Fast spin echo pulse sequence was used for 
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T2-weighted imaging with following parameters: TR = 4.7 s and effective TE = 22.4 ms, echo 
train length = 8 echos. Multiple slice 2D images were acquired with in-plane imaging matrix 
192 x 168 and field of view 20 x 20 mm2. Thickness of slices was 0.4 mm without gap 
between slices. Slice number was 60, covering the whole brain. The imaging resolution was 
0.1 x 0.12 x 0.4 mm3. A total of six mice per group were scanned. The images were 
processed using Amira (TGS, San Diego, CA, USA). The entire brain and the ventricles were 
manually delineated for each slice and their 3D volumes were measured. 
Dendritic spine analysis  
Dendritic spines labeling was performed as in (23). Briefly, DiI (1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine perchlorate crystals, Invitrogen, USA) was dissolved in 
methylene chloride (Supelco), dropped onto the tungsten particles (1.3 mm in diameter; Bio-
Rad). Dil-coated particles were injected in Tygon tubing subsequently cut into small pieces 
(bullets). Mice were anesthetized with an intraperitoneal injection of Avertin and perfused 
with PBS, and then with 4% PFA in 0.1 M PB. Brains were postfixed in the same solution, 
washed several times in PB 0.1 M, and then cut into 300 µm sections on a vibratome 
(Leica VT 1000S). An helios gene gun system (Bio-Rad) was used to propel Dil-coated 
particles into fixed slices. After the shot, the slices were placed in 4% PFA for 2 h, washed 
three times in PB 0.1 M, mounted on glass slides. Images from fluorescently labeled apical 
dendrites (100-200 µm from the soma) in the CA1 region of hippocampus were acquired 
using a LSM-5 Pascal confocal microscope (Zeiss, Göttingen, Germany) with HeNe (543 
nm) laser. To generate the dataset, ≥10 z-stack images consisting of 10–15 sections (512 × 
512 pixels, 80 to 100 µm-long dendritic segments) spaced 0.5 µm apart were collected for 
each animal. Dendritic segments and spines were analyzed with ImageJ software (NIH, 
public domain), with an observer blinded to the genotype and experimental conditions. Spine 
were classified as filopodia (protrusions without an enlargement of the tip), thin (protrusions 
with a head smaller than spine length), mushroom (large head spines with a neck) or stubby 
(large head spines without a neck). Only dendritic protrusions that were clearly projecting out 
of the shaft were measured. The following morphological parameters were calculated: 
density of specific spine classes, neck lenght (the linear distance from the junction with 
the dendritic shaft to that with the spine head) and head diameter (measured along the 
dimension that maximized head width). Density analysis were expressed as number of 
dendritic spine/µm.  
 
Statistical analysis and graph representation. 
Two-way analyzes of variance (ANOVA) followed by Bonferroni or Sidak’s post hoc multiple 
comparison tests were used to analyze the contribution of the genotype and the treatment to 
the variability of each test. One sample t-test was also used to complete the analysis of the 
Recognition index and the dendritic spine phenotypes. Only significant results are detailed. 
We used GraphPad Prism (La Jolla, CA, USA) to perform statistical analyses and draw 
graphical representations. 
In all figures, data are presented with histogram bars expressing the mean together with the 
standard error of the mean (sem). *: significant difference between genotypes (Ophn1+/y and 
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Ophn1-/y mice); #: significant difference between treated (Fasudil) and untreated mice 
(Control=Vehicle); $: significant difference with theoretical value (p<0.05).  
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 Figure Legends: 
Figure 1: RHOA/ROCK signalling pathway and therapeutic schemas.  
A. RHOA/ROCK signalling pathway and its inhibition by OPHN1 and by Fasudil 
(HA1077). RHO: RAS homolog GTPase, ROCK: RHO kinase, MYPT1: Myosin 
phosphatase target subunit 1, MLC: myosin light chain. 
 
B. First therapeutic scheme: 17 weeks-old (w) males were treated for 12 weeks with a 
daily dose of 3mg of Fasudil by oral administration. One month after the initial start 
animals were tested for their behaviour in motor and cognitive tasks that last for 8 
weeks before analyses of brain anatomy using Magnetic Resonance Imagery (MRI). 
 
C. Second therapeutic scheme: 8 weeks-old (w) males were treated for 12 weeks with a 
daily dose of 3mg of Fasudil by oral administration. At the end of the protocol, 
animals were perfused with fixative for dendritic spines analyses. 
 
Figure 2: Fasudil rescues hyperactivity in Ophn1-/y mice. 
A. Mean time of latency before falling from the axis in the rotarod test. (n=10-11 mice per 
group). 
B. and C.  Mean rearing activity during the 5 first minutes after the introduction of the 
animals to the elevated-plus maze (B.) or the open field in the object recognition test 
(Habituation phase) (C.), (n=10-11 mice per group). 
D. Mean activity of locomotion in the open field during the first five minutes (n=10-11 
mice per group). 
Figure 3: Recognition but not working and spatial memories are improved upon Fasudil 
treatment:  
 A. Recognition index (%) as measured during the retention phase in the object 
recognition task. 
B. Working memory measured by the spontaneous alternation rate (%) in the Y maze. 
C. and D. Spatial reference learning and memory measured by the distance to reach the 
hidden platform during 5 days of training (C.) and by the number of platform crosses (D.) 
Statistical comparisons *: Ophn1-/y vs Ophn1+/y. $: Statically different from the chance 
(50, line in hyphen). 
Figure 4: Fasudil rescues brain ventricular dilatation in Ophn1-/y mice 
 by guest on M
ay 5, 2016
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
	 18	
A. Delineation of the brain ventricles on MRI slice (filled in red) 
B. Mean size of the ventricular normalized to untreated Ophn1+/y. Statistical comparisons 
*: Ophn1-/y vs Ophn1+/y, (n=4-6 mice per group). 
C. Delineation of the whole brain on MRI slice (surrounded in red) 
D. Mean volume of whole brain (in mm3), (n=4-6 mice per group)  
Figure 5: Fasudil treatment differentially affects dentritic spine density and morphology 
according to genotype. 
A. Representative confocal micrograph showing DiOlistic fluorescent labeling of dendritic 
spines protruding from apical dendrites (100-200 µm from the soma) of CA1 pyramidal 
neurons in Ophn1-/y and Ophn1+/y mice treated with Fasudil or vehicle. Scale bar 5 µm. 
(B, C, D) Spine density. Quantitative analysis of the density of filopodia- (B), thin-(C) and 
mushroom-shaped (D) spines in control and Fasudil-treated mice of both genotypes.  
(E, F) Spine Morphology. Quantitative analysis of the mean head diameter of thin spines 
(E) and mean neck length of mushroom-shaped spines (F) in CA1 pyramidal neurons in 
control and Fasudil-treated animals of both genotypes.  
Statistical comparisons: Bonferroni post-tests. *: p < 0.05, Ophn1-/y vs Ophn1+/y and #: p 
< 0.05, untreated vs treated. 
Supplemental data1:  
Hyperactivity recorded during during the first ten minutes of the acquisition trial in the object 
recognition task. Left: mean distance in meters (m); Right: number of rears. 
Supplemental data2:  
A. Post-natal compensation of dendritic spine deficit in Ophn1-/y mice; differences between 
genotype were extrapolated from data in (9, 10)  
B. Developmental model of dendritic spine according to genotype. The first months after birth 
are characterized by the elimination of an excessive number of synapses and by intense 
remodeling of dendritic spines. Loss of Ophn1 would accelerate this maturation by increasing 
RHO activity and retraction of spines compared to “normal” RAC activation. Meanwhile the 
increase of PKA activity secondary to the inactivation of Ophn1 will inhibit RHOA/ROCK 
activation back to controls (5 months). In the presence of Fasudil the balance between RHO 
and RAC would be differentially affected according to genotype due to Fasudil inhibition of 
both PKA and ROCK. 
C. Model negative regulation of RHO GTPase signaling by PKA. RHOA phosphorylation by 
PKA inhibits its binding to ROCK but not to CITRON. Fasudil not only inhibits ROCK but also 
PKA. In the presence of OPHN1, both RHOA/ROCK and RHOA/CITRON pathways are 
inhibited by Fasudil, resulting in the RAC hyperactivation and spine growth. In the absence of 
OPHN1, treatment by Fasudil inhibits both PKA and ROCK but RHOA/CITRON, which is still 
activated leading to spine retraction. 
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Abbreviations:  
Intellectual Disability (ID), Intelligence Quotient (IQ) , Autism Spectrum Disorder (ASD), 
Central Nervous System (CNS), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptor (AMPAR), Post-Synaptic Density (PSD), type1-metabolotropic receptors (mGluR1),  
Long Term Depression (LTD), myosin phosphatase target subunit-1 (MYPT1), the Myosin 
light chain (MLC). 
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